Opko Health's ModeX Forms Licensing and Collaboration Partnership with Regeneron
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 29 2025
0mins
Collaboration Announcement: ModeX Therapeutics, a subsidiary of OPKO Health, has entered into a licensing and collaboration agreement with Regeneron Pharmaceuticals.
Focus of Collaboration: The partnership aims to discover and develop multispecific antibodies targeting various therapeutic indications using ModeX's MSTAR platform and Regeneron's proprietary binders.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like REGN with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on REGN
Wall Street analysts forecast REGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for REGN is 808.50 USD with a low forecast of 637.00 USD and a high forecast of 1057 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
16 Buy
6 Hold
0 Sell
Moderate Buy
Current: 751.130
Low
637.00
Averages
808.50
High
1057
Current: 751.130
Low
637.00
Averages
808.50
High
1057
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Regeneron Pharmaceuticals Set to Announce Q4 Earnings
- Earnings Announcement: Regeneron Pharmaceuticals is set to release its Q4 2023 earnings on January 30 before market open, with consensus EPS estimate at $10.64, reflecting an 11.8% year-over-year decline, and revenue estimate at $3.78 billion, down 0.3% year-over-year.
- Historical Performance: Over the past two years, Regeneron has surpassed EPS and revenue estimates 75% of the time, indicating strong performance and stability in market expectations, which bolsters investor confidence.
- Estimate Revisions: In the last three months, EPS estimates have seen 14 upward revisions and 4 downward revisions, while revenue estimates have experienced 15 upward revisions with no downward adjustments, reflecting analysts' optimistic outlook on Regeneron's future performance.
- Industry Conference Participation: Regeneron will present at the 44th Annual J.P. Morgan Healthcare Conference, further showcasing its leadership position and strategic direction in the biopharmaceutical sector.
Continue Reading
Alvotech Settles Patent Disputes with Regeneron and Bayer
- Global Patent Settlement: Alvotech has reached a licensing and settlement agreement with Regeneron and Bayer, resolving all remaining patent disputes related to its Eylea biosimilar, thereby ensuring its legitimacy and competitiveness in global markets.
- Market Entry Timeline: Under the agreement, Alvotech will launch the biosimilar in the UK and Canada starting January 1, 2026, and in the EEA and other countries (excluding the U.S.) and Japan (excluding DME) from May 1, 2026, significantly expanding its market reach.
- U.S. Market Outlook: Alvotech has secured a Q4 2026 license entry date for the U.S. market, pending regulatory approval, which lays a foundation for future revenue growth and reflects its strategic positioning in the biopharmaceutical sector.
- Confidential Terms Impact: While the remaining terms of the agreement remain confidential, the settlement provides a stable market environment for Alvotech and its commercial partners, enhancing their competitive advantage in the biosimilar market.
Continue Reading